BIVI

BioVie Inc

2.00

Sep 04 • 3:59 PM ET -0.03 (-1.48%)

2.00

Aftermarket • 7:58 PM ET -0.00 (-0.02%)

Healthcare Biotechnology USA Nano NASD

Peers: AIM APRE BCDA CALC CVM KAPA KPRX NEUP GOVX JAGX

| Held by: VXF

Index	-
Market Cap	16.90M
Enterprise Value	8.20M
Income	-22.12M
Sales	0.00M
Book/sh	1.36
Cash/sh	1.06
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	13
IPO	May 05, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.47
P/C	1.88
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	3.59
Current Ratio	3.59
Debt/Eq	0.03
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-3.20
EPS next Y	-0.57
EPS next Q	-
EPS this Y	47.06%
EPS next Y	9.52%
EPS next 5Y	22.68%
EPS past 3/5Y	72.98% 70.98%
Sales past 3/5Y	- -
EPS Y/Y TTM	78.51%
Sales Y/Y TTM	-
EPS Q/Q	58.93%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	0.00% -

Insider Own	5.04%
Insider Trans	5.78%
Inst Own	25.78%
Inst Trans	2.85%
ROA	-123.27%
ROE	-150.76%
ROIC	-211.13%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	12.85%
SMA50	15.56%
SMA200	33.91%
Trades

Shs Outstand	8.45M
Shs Float	8.03M
Short Float	15.62%
Short Ratio	0.28
Short Interest	1.25M
52W High	3.79 -47.23%
52W Low	0.82 143.90%
Volatility	9.39% 27.96%
ATR (14)	0.34
RSI (14)	54.81
Beta	0.70
Rel Volume	0.07
Avg Volume	4.55M
Volume	296,762

Perf Week	-7.41%
Perf Month	48.15%
Perf Quarter	25.00%
Perf Half Y	47.06%
Perf YTD	72.41%
Perf Year	25.79%
Perf 3Y	-99.35%
Perf 5Y	-99.74%
Perf 10Y	-99.94%
Recom	1.00
Target Price	27.75
Prev Close	2.03
Price	2.00
Change %	-1.48%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-22-22	Initiated	Cantor Fitzgerald	Overweight	$7
Jan-15-21	Initiated	B. Riley Securities	Buy	$47

Aug-31-26 09:48AM	Dow falls as US strikes Iran, rate-hike bets jump (Proactive) +5.56%
09:05AM	BioVie completes final patient visit in Phase 2 Long COVID trial (Proactive)
08:00AM	BioVie Announces Completion of Treatment Phase of ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID (GlobeNewswire)
Aug-07-26 01:13PM	Parkinson's drug developers are betting big on inflammation (Proactive) -25.98%
07:05AM	BioVie stock sinks on Phase IIb Parkinsons trial data (Clinical Trials Arena)
09:03AM	Loading…
Aug-06-26 09:03AM	BioVie reports positive Phase 2 results for Parkinson's candidate bezisterim (Proactive) -33.82%
07:30AM	BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson's Disease (GlobeNewswire)
Aug-05-26 12:18PM	BioVie reports positive phase 2 Parkinson's results, eyes pivotal Phase 3 trial (Proactive) +11.48%
Jun-05-26 03:31PM	Did BioVie Inc. Insiders Breach their Fiduciary Duties to Shareholders? (PR Newswire) -6.98%
May-29-26 04:30PM	BioVie: Long COVID trial fully enrolled ICYMI (Proactive)
May-27-26 08:00AM	Join BioVie's Exclusive Live Investor Webinar and Q and A Session on June 2 (GlobeNewswire)
May-26-26 01:34PM	BioVie completes enrollment in Long COVID trial as need for treatments grows (Proactive) -5.26%
09:12AM	BioVie completes enrollment in Phase 2 Long COVID trial (Proactive)
08:00AM	BioVie Announces Full Enrollment of the ADDRESS-LC Trial of Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID (GlobeNewswire)
May-19-26 08:31AM	BioVie completes final patient visit in Parkinson's drug trial (Proactive)
08:00AM	Loading…
May-18-26 08:00AM	BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's Disease (GlobeNewswire)
May-09-26 09:00AM	BioVie CEO shares insights into long COVID trial - ICYMI (Proactive)
May-04-26 11:24AM	BioVie advances long COVID trial, top-line data expected by summer (Proactive)
Apr-27-26 08:00AM	BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026 (GlobeNewswire) +6.00%
Apr-14-26 08:00AM	BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual Meeting (GlobeNewswire) +5.80%
05:10AM	BioVie abstract on Parkinsons drug accepted for neurology conference (Proactive)
03:52AM	Nasdaq jumps, Dow heads higher with Iran talks and earnings in focus (Proactive)
Apr-11-26 07:27AM	BioVie CEO explains Bezisterim Parkinsons trial results - ICYMI (Proactive)
Apr-09-26 01:44PM	BioVie targets neuroinflammation and insulin resistance in Parkinsons treatment approach (Proactive)
Mar-26-26 11:00AM	BioVie targets Parkinsons at its source with lead drug bezisterim (Proactive)
Mar-12-26 09:05AM	BioVie to present Parkinsons study data at AD/PD 2026 conference (Proactive)
08:00AM	BioVie Announces Abstract Accepted for Presentation at AD/PD 2026 (GlobeNewswire)
Feb-23-26 08:00AM	Join Biovie's Exclusive Live Investor Webinar and Q&A Session on March 4 (GlobeNewswire)
Feb-12-26 03:50PM	Dow drops below 50,000 as S&P 500 falls back under years opening level (Proactive)
08:33AM	BioVie highlights bezisterim research at ACP meeting (Proactive)
08:00AM	Loading…
08:00AM	BioVie Announces Abstracts Accepted for Presentation at the 2026 American College of Psychiatrists Annual Meeting (GlobeNewswire)
Feb-11-26 10:30AM	BioVie could offer first new Parkinsons therapy in decades (Proactive)
Jan-08-26 08:00AM	BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson's Disease (GlobeNewswire)
Dec-24-25 02:05PM	HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Dec-11-25 12:00PM	What Makes BioVie (BIVI) a New Buy Stock (Zacks)
Nov-19-25 08:00AM	Join Biovie's Exclusive Live Investor Webinar and Q&A Session on December 9 (GlobeNewswire)
Oct-24-25 08:20AM	Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Sep-26-25 08:00AM	BioVie to Host Live Investor Webinar and Q&A on Oct. 8 (GlobeNewswire)
Aug-13-25 04:05PM	BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes (GlobeNewswire)
Aug-11-25 04:05PM	BioVie Inc. Announces Closing of $12 Million Public Offering (GlobeNewswire) +7.19% -6.70%
Aug-07-25 08:43PM	BioVie Inc. Announces Pricing of $12 Million Public Offering (GlobeNewswire) -25.58% -42.61%
Jul-24-25 08:00AM	BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology (GlobeNewswire) -8.37%
Jul-22-25 08:00AM	BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors (GlobeNewswire) +12.04%
Jul-09-25 08:00AM	BioVie Announces Data Highlighting Bezisterim's Potential to Slow or Reverse Biological Aging and Neurodegeneration Featured as a Keynote Talk at the 7th World Aging and Rejuvenation Conference (GlobeNewswire)
Jun-26-25 08:00AM	BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders Congress (ATMRD) (GlobeNewswire)
Jun-24-25 04:05PM	BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders Congress (GlobeNewswire) +5.94%
May-15-25 08:00AM	BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID (GlobeNewswire)
May-14-25 07:30AM	BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025 (GlobeNewswire)
May-07-25 08:00AM	BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson's Disease and Related Disorders (IAPRD 2025) (GlobeNewswire) -6.90%
May-05-25 08:00AM	BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth (GlobeNewswire) -5.79%
Apr-16-25 08:00AM	BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson's Disease with First Patient Enrolled (GlobeNewswire)
Mar-27-25 08:00AM	BioVie to Host KOL Investor Webcast to Discuss the Long COVID Treatment Landscape and its ADDRESS-LC Trial on April 10, 2025 (GlobeNewswire)
Mar-10-25 10:35AM	New to The Street Show 633 to Broadcast on Fox Business Network as Sponsored Programming Tonight at 10:30 PM PST Featuring Zapp Electric Vehicles ($ZAPP), BioVie ($BIVI), PetVivo ($PETV), and Banzai ($BNZI) (ACCESS Newswire) -8.40%
Mar-03-25 08:40PM	New to the Street Airs Show #630 on Fox Business Network Tonight at 10:30 PM PST Featuring Roadzen ($RDZN), BioVie ($BIVI), AtlasClear (ATCH), eXoZymes ($EXOZ), and EvolveHealthandLifestyle.com With Craig Bruce (ACCESS Newswire) -11.28%
Feb-22-25 12:15PM	New to The Street to Broadcast Live on Bloomberg Tonight at 6:30 PM EST as Sponsored Programming, Spotlighting BioVie (BIVI), RoadZen (RDZN), HPB, and Sustainable Innovation With Shark Tanks Kevin Harrington and Sustainable Green Team (SGTM) (ACCESS Newswire)
Jan-13-25 09:00AM	BioVie Inc. ($BIVI) Joins Forces With New to The Street for a Dynamic 6-Part Media Campaign Featuring Long-Form Interviews, National TV Commercials, Iconic Billboards, and Exclusive Accredited Events (ACCESS Newswire)
Nov-20-24 08:00AM	BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference (GlobeNewswire)
Nov-04-24 08:00AM	BioVie's Upcoming Parkinson's Disease Clinical Trial is Fully Funded (GlobeNewswire) -9.39%
Oct-29-24 04:05PM	BioVie Inc. Announces Closing of Registered Direct Offering (GlobeNewswire) -10.80% +10.94%
Oct-28-24 04:10PM	UPDATE -- BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
03:13PM	BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Oct-24-24 04:10PM	BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) +5.45% +5.54%
Oct-23-24 03:24PM	BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -23.51%
09:19AM	BioVie Announces Stock Offering and Private Placement (TipRanks)
08:00AM	Join BioVie's Exclusive Live Investor Webinar and Q&A Session on November 7th, 2024 (GlobeNewswire)
Oct-22-24 04:01PM	BioVie Inc. Announces Closing of Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) +27.76%
Oct-21-24 03:08PM	BioVie Inc. Announces Pricing of Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) +11.91%
Oct-15-24 08:00AM	BioVie Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin (GlobeNewswire)
Oct-11-24 09:00AM	BioVie and Genetic Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Oct-01-24 08:00AM	BioVie Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin (GlobeNewswire)
Sep-25-24 04:05PM	BioVie Inc. Announces Closing of Public Offering (GlobeNewswire) -7.50%
Sep-23-24 10:26PM	BioVie Inc. Announces Pricing of Public Offering (GlobeNewswire) -57.86%
04:05PM	BioVie Inc. Announces Proposed Public Offering (GlobeNewswire)
Sep-16-24 08:00AM	BioVie Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long COVID (GlobeNewswire)
Sep-03-24 08:00AM	BioVie Announces FDA Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long COVID (GlobeNewswire)
Aug-27-24 08:45AM	BioVie Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process at the 11th Aging Research and Drug Discovery Meeting (GlobeNewswire)
Aug-13-24 08:00AM	BioVie to Present Overview of Bezisterim Clinical Data on Longevity at 11th Aging Research and Drug Discovery Meeting (GlobeNewswire)
Aug-12-24 07:30AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -10.08%
Aug-08-24 06:00AM	BioVie Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson's Disease (GlobeNewswire) +13.30%
Aug-06-24 04:40PM	BioVie Inc. Announces Reverse Stock Split (GlobeNewswire) -21.40% -5.63%
Jul-05-24 09:00AM	BioVie and bioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jun-25-24 08:00AM	BioVie Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at ATMRD 2024 (GlobeNewswire) -5.32%
Jun-21-24 09:00AM	BioVie and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Jun-20-24 08:00AM	BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress (GlobeNewswire)
Jun-12-24 08:24AM	Join BioVie's Exclusive Live Investor Webinar and Q&A Session on June 26 (GlobeNewswire)
Jun-04-24 08:00AM	BioVie Announces Formation of Advisory Board for Bezisterim in Long COVID (GlobeNewswire)
May-22-24 08:00AM	BioVie's Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson's Disease Patients (GlobeNewswire)
May-15-24 10:53AM	BIVI Stock Earnings: BioVie Beats EPS for Q3 2024 (InvestorPlace)
Apr-29-24 11:43AM	BioVie Gets up to $13.1 Million From US Defense Department to Evaluate Bezisterim for Long COVID (MT Newswires)
08:00AM	BioVie Awarded up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID (GlobeNewswire)
Apr-25-24 08:00AM	BioVie Presents Data Showing Potential for Bezisterim (NE3107) to Reduce Inflammation and Restore Homeostasis in a Manner Correlated with Alzheimer's Disease and Biomarker Endpoints (GlobeNewswire)
Apr-18-24 08:00AM	BioVie to Present Data Showing How NE3107 Potentially Restores Homeostasis via Specific Genes Associated with Dementia, Metabolism, and Inflammation (GlobeNewswire)
Apr-12-24 09:00AM	Genetic Technologies and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESSWIRE)
Mar-26-24 10:30AM	Lawsuit Notice: Investors who lost money with BioVie Inc. (NASDAQ: BIVI) shares should contact the Shareholders Foundation (PR Newswire) -6.17%
Mar-13-24 11:30AM	SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of BioVie (PR Newswire) +6.93%
Mar-12-24 09:55AM	Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now (Zacks)
09:41AM	BioVie Sued By Block & Leviton LLP for Securities Law Violations (GlobeNewswire)
Mar-11-24 10:48AM	BioVie cuts 'most de-risked program,' will seek partners for phase-3 ready ascites program (FierceBiotech.com)
08:00AM	BioVie Announces Pipeline Update and Near-Term Clinical Priorities (GlobeNewswire)
Mar-06-24 06:21PM	BIVI INVESTORS: Lead Plaintiff is Quickly Approaching; Contact Robbins LLP for Information About Your Rights (GlobeNewswire) -8.02% -10.25%

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders, and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

PresidentMr. Cuong Viet Do M.B.A.

CFOMs. Joanne Wendy Kim CPA

Executive VP of R&D and Chief Medical OfficerDr. Joseph M. Palumbo M.D.

Senior Vice President of OperationsMr. Clarence N. Ahlem

Senior Vice President of Liver Disease & Long COVID ProgramsDr. Penelope Markham Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Palumbo Joseph M	Chief Medical Officer	Aug 28 '26	Buy	2.16	4,843	10,461	6,036	Aug 28 09:01 PM
Chappell Amy Suzon	Director	Aug 28 '26	Buy	2.16	727	1,570	727	Aug 28 09:01 PM
KIM JOANNE WENDY	Chief Financial Officer	Aug 28 '26	Buy	2.18	2,500	5,450	3,441	Aug 28 08:58 PM
DO CUONG V	President & CEO	Aug 27 '26	Buy	2.08	15,210	31,637	16,117	Aug 28 08:57 PM

Open in Screener

ADAG

Adagene Inc ADR

3.58

Sep 04 • 3:59 PM ET -0.11 (-2.98%)

3.58

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology China Micro NASD

Peers: CAMP CNTN IFRX PLYX PRQR RNA TLSA KPTI CNTX TENX

| Held by: PGJ

Index	-
Market Cap	240.36M
Enterprise Value	135.09M
Income	-20.56M
Sales	9.32M
Book/sh	1.33
Cash/sh	1.91
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	128
IPO	Feb 09, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	25.79
P/B	2.69
P/C	1.88
P/FCF	-
EV/EBITDA	-
EV/Sales	14.49
Quick Ratio	5.02
Current Ratio	5.02
Debt/Eq	0.06
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-0.38
EPS next Y	-0.67
EPS next Q	-0.28
EPS this Y	-65.33%
EPS next Y	-35.48%
EPS next 5Y	-27.24%
EPS past 3/5Y	41.25% 21.03%
Sales past 3/5Y	-6.07% 61.40%
EPS Y/Y TTM	41.48%
Sales Y/Y TTM	8906.15%
EPS Q/Q	-
Sales Q/Q	-
Earnings	Aug 12 BMO
EPS/Sales Surpr.	0.00% 0.00%

Insider Own	19.09%
Insider Trans	0.20%
Inst Own	18.90%
Inst Trans	41.47%
ROA	-20.55%
ROE	-28.57%
ROIC	-19.17%
Gross Margin	94.22%
Oper. Margin	-240.31%
Profit Margin	-220.66%
SMA20	-6.41%
SMA50	-6.66%
SMA200	10.93%
Trades

Shs Outstand	67.14M
Shs Float	54.33M
Short Float	3.89%
Short Ratio	7.90
Short Interest	2.11M
52W High	4.85 -26.19%
52W Low	1.30 175.38%
Volatility	5.62% 6.71%
ATR (14)	0.26
RSI (14)	42.37
Beta	0.53
Rel Volume	0.11
Avg Volume	267.19K
Volume	28,194

Perf Week	-2.72%
Perf Month	-13.53%
Perf Quarter	7.83%
Perf Half Y	26.06%
Perf YTD	89.42%
Perf Year	67.29%
Perf 3Y	159.42%
Perf 5Y	-78.65%
Perf 10Y	-
Recom	1.40
Target Price	10.86
Prev Close	3.69
Price	3.58
Change %	-2.98%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-24-25	Initiated	Guggenheim	Buy	$9
Aug-06-25	Initiated	Leerink Partners	Outperform	$7
Jan-31-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-25-21	Initiated	China Renaissance	Buy	$40.57
Mar-08-21	Initiated	Morgan Stanley	Overweight	$34
Mar-08-21	Initiated	Jefferies	Buy	$33
Mar-08-21	Initiated	Goldman	Buy	$29

Aug-20-26 08:00AM	Adagene to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-12-26 07:30AM	Adagene Reports Six Months 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-12-26 08:30AM	Adagene to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Apr-17-26 04:01PM	Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug's Potential as a Backbone Combination Therapy for Multiple Tumor Types (GlobeNewswire)
Apr-14-26 07:00AM	Adagene Adds Industry Veteran Peter Lebowitz to Scientific and Strategic Advisory Board (GlobeNewswire)
07:10AM	Loading…
Apr-02-26 07:10AM	Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs (GlobeNewswire) -13.45%
07:01AM	Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) (GlobeNewswire)
07:00AM	Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response (GlobeNewswire)
Apr-01-26 05:00PM	Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +17.60%
Mar-17-26 04:35PM	Adagene's Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA (GlobeNewswire)
Feb-25-26 05:25PM	Adagene Spotlights ADG126+KEYTRUDA Data, Late-Line MSS-CRC Focus in Oppenheimer Conference Talk (MarketBeat) -5.67%
Feb-17-26 09:27AM	Adagene to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Feb-16-26 07:48AM	Moderna's Shares Climb 5.3% as Investors Revisit Biotech Leaders (Zacks)
Jan-23-26 08:00AM	Adagene Provides Business Update and 2026 Objectives (GlobeNewswire) +22.66%
Dec-17-25 08:43AM	FDA Grants Fast Track Designation to ADAG's Colorectal Cancer Drug (Zacks)
07:00AM	Loading…
Dec-16-25 07:00AM	Adagene Announces FDA Fast Track Designation for Muzastotug (ADG126) (GlobeNewswire) +13.77%
Nov-13-25 07:00AM	Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody Technology (GlobeNewswire)
Oct-31-25 07:00AM	Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA (pembrolizumab) in Microsatellite Stable Colorectal Cancer (GlobeNewswire) -7.29%
Sep-30-25 12:00PM	All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy (Zacks)
Sep-25-25 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Sep-16-25 08:00AM	Adagene Expands SAFEbody Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate (GlobeNewswire)
Sep-08-25 04:59PM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) +8.64%
Sep-05-25 09:55AM	Adagene's ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China (GlobeNewswire)
Sep-03-25 09:05AM	Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor (GlobeNewswire)
Aug-26-25 08:05AM	Adagene to Participate in Two Investor Conferences in September (GlobeNewswire)
Aug-21-25 09:40AM	Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? (Zacks) +10.14%
Aug-12-25 04:05PM	Adagene Reports Six Months 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) -16.59% -13.61%
Jul-15-25 07:00AM	Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA (GlobeNewswire)
Jul-08-25 07:00AM	Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate (GlobeNewswire)
Jul-01-25 07:00AM	Adagene announces up to $25 million strategic investment from Sanofi (GlobeNewswire) -5.13%
09:40AM	Loading…
Jun-03-25 09:40AM	Is McKesson (MCK) Outperforming Other Medical Stocks This Year? (Zacks)
May-27-25 07:30AM	Adagene to Present at Jefferies Global Healthcare Conference 2025 (GlobeNewswire)
May-22-25 05:05PM	Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +12.00%
Apr-28-25 08:00AM	Adagene Appoints John Maraganore, Ph.D. as Executive Advisor (GlobeNewswire)
Apr-23-25 10:05AM	Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-07-25 08:00AM	Adagene to Present at Stifel's 2025 Virtual Targeted Oncology Forum (GlobeNewswire)
Mar-24-25 08:00AM	Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.04%
Mar-13-25 08:00AM	Adagene to Present at 11th Annual Immuno-Oncology 360 Summit (GlobeNewswire)
Mar-06-25 08:00AM	Adagene to Present at Leerink's Global Healthcare Conference 2025 (GlobeNewswire)
Feb-27-25 08:00AM	Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer (GlobeNewswire)
Jan-27-25 07:00AM	Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-21-25 05:00PM	Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-14-25 08:00AM	Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025 (GlobeNewswire)
Jan-08-25 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.34%
Dec-06-24 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Nov-20-24 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.86%
Nov-07-24 10:01AM	Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire)
Oct-09-24 06:00AM	Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire)
Sep-16-24 03:01AM	Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) in Combination with KEYTRUDA (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (GlobeNewswire) -21.20%
Sep-11-24 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Aug-29-24 07:00AM	Adagene to Participate in Investor Conferences in September (GlobeNewswire)
Aug-26-24 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-25-24 04:05PM	Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update (GlobeNewswire) -7.50%
Jul-12-24 07:00AM	Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September (GlobeNewswire)
May-22-24 04:45PM	Adagene to Present at Investor Conferences in June (GlobeNewswire) +6.90%
Mar-29-24 09:00AM	Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-24 04:01PM	Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board (GlobeNewswire)
Feb-27-24 08:00AM	Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-09-24 06:00AM	Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with KEYTRUDA (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (GlobeNewswire) +5.14%
Jan-17-24 07:00AM	Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (PR Newswire) +5.82%
Jan-16-24 05:01PM	Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (GlobeNewswire) +19.24%
Jan-04-24 05:00AM	Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium (GlobeNewswire)
Nov-03-23 12:00PM	Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126 at SITC 2023 (GlobeNewswire)
Oct-30-23 09:40AM	Are Medical Stocks Lagging Boston Scientific (BSX) This Year? (Zacks)
Oct-13-23 09:40AM	Are Medical Stocks Lagging Medpace (MEDP) This Year? (Zacks)
Oct-12-23 08:00AM	Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) -6.04%
Sep-27-23 09:40AM	Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? (Zacks) +10.14%
Sep-07-23 10:45PM	Adagene to Present at Investor and Scientific Conferences in September (PR Newswire)
09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Aug-31-23 07:32AM	Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update (GlobeNewswire) +15.25%
May-25-23 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) -7.22%
May-04-23 09:00AM	Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate (GlobeNewswire)
Apr-28-23 07:00AM	Adagene Announces Updates to its Board of Directors (GlobeNewswire)
Apr-18-23 09:17AM	Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors (GlobeNewswire)
Mar-31-23 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
06:34AM	Adagene Full Year 2022 Earnings: US$1.85 loss per share (vs US$1.83 loss in FY 2021) (Simply Wall St.)
Mar-28-23 04:30PM	Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +5.84%
Mar-14-23 06:00PM	Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April (GlobeNewswire) +5.15% +11.89%
Mar-05-23 07:39PM	Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board (GlobeNewswire)
Jan-09-23 07:00AM	Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial (GlobeNewswire) +11.25%
Jan-05-23 04:01PM	Adagene to Present at the Biotech Showcase 2023 in San Francisco on January 9 (GlobeNewswire) +5.11% +11.11%
Dec-16-22 06:30AM	Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roches Standard-of-Care for First-Line Advanced Liver Cancer (GlobeNewswire) +10.61%
Nov-21-22 04:05PM	Adagene Appoints Cuong Do to Board of Directors and Audit Committee (GlobeNewswire)
Nov-10-22 09:05AM	Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors (GlobeNewswire)
Oct-11-22 04:03PM	Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody, ADG116, at Upcoming Society for Immunotherapy of Cancers (SITC) Annual Meeting in November (GlobeNewswire) -7.63% +6.61%
Sep-10-22 04:13AM	Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors (GlobeNewswire)
Aug-30-22 05:25PM	Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates (GlobeNewswire)
Jun-29-22 04:05PM	Adagene Announces Authorization of Share Repurchase Program up to US$10 Million (GlobeNewswire)
May-26-22 09:30PM	Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels (PR Newswire)
May-12-22 07:00AM	Adagene to Participate in Investor Conferences in May and June (GlobeNewswire)
May-02-22 06:06AM	Shareholders in Adagene (NASDAQ:ADAG) are in the red if they invested a year ago (Simply Wall St.)
Apr-08-22 01:09PM	Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire)
Apr-03-22 02:34PM	10 Best Non-Tech Chinese Stocks to Buy Now (Insider Monkey)
Mar-31-22 08:30AM	Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-17-22 10:42AM	Adagene (ADAG) Gets FDA Nod for Cancer Study on ADG126 Combo (Zacks)
Mar-16-22 10:00AM	Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors (Benzinga)
07:00AM	Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab (PR Newswire)
Mar-08-22 09:21PM	Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Mar-02-22 08:22AM	Sanofi to pay up to $2.5 billion in deal with Adagene (MarketWatch)
06:00AM	Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates (PR Newswire)

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

Co- FounderDr. Peter P. Luo Ph.D.

CFO & DirectorMr. Man Kin Tam M.B.A.

Executive Director & Head of Human ResourcesMs. Ling Zhou

Chief Manufacturing OfficerDr. Qinghai Zhao Ph.D.

Chief Strategy OfficerMr. Mickael Chane-Du

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GU CHUNFANG	Officer	Aug 20 '26	Proposed Sale	3.95	40,000	158,000		Aug 19 10:22 AM
DO CUONG V	Director	Aug 14 '26	Buy	3.75	2,000	7,500	2,000	Aug 18 06:11 PM
Luo Peter	Chief Executive Officer	Aug 04 '26	Buy	3.65	22,966	83,746	67,966	Aug 06 06:15 PM
Luo Peter	Chief Executive Officer	Aug 05 '26	Buy	3.65	279	1,018	68,245	Aug 06 06:15 PM

BIVI

BioVie Inc

ADAG

Adagene Inc ADR

Upgrade your Finviz experience